WEDNESDAY, Aug. 27, 2025 (HealthDay News) — Eli Lilly says its new once-daily pill, orforglipron, helped people lose ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5% ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.